Corline Biomedical
14,1 SEK -1,74 %Vær den første som følger denne virksomhed
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Omsætning
23,55 mio.
EBIT %
9,89 %
P/E
128,18
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CLBIO
Daglig lav / høj pris
14 / 14,5
SEK
Markedsværdi
303,02 mio. SEK
Aktieomsætning
151,7 t SEK
Volumen
11 t
Finanskalender
Delårsrapport
25.08.2023
Delårsrapport
10.11.2023
Årsrapport
14.02.2024
Viser Alle indholdstyper
Intet indhold